|
InnoCare Pharma Limited is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer and autoimmune diseases. The company operates a biopharmaceutical platform with in-house research and development capabilities, targeting both novel and evidence-based biological pathways. Its drug portfolio includes three launched products, with ongoing clinical trials and registration filings for Orelabrutinib in China and the U.S. The company also develops other clinical-stage candidates, including the TL1A/IL-23p19 bispecific antibody ICP-B161 and the combination of Metoclopramide and Orelabrutinib for marginal zone lymphoma. InnoCare Pharma serves patients in China and the U.S., with a focus on unmet clinical needs in hematological malignancies, solid tumors, and autoimmune conditions. Summarised from the company's own disclosures, fiscal year ended Apr 2026 |
Industry Biotechnology | Homepage innocarepharma.com |
| Sector Healthcare | IR page innocarepharma.com/investor/esg | |
|
Tags
oncology, autoimmune diseases, bispecific antibodies, hematological malignancies, solid tumors, drug discovery, clinical development, commercialization, Orelabrutinib, ICP-B161, Metoclopramide
|
Press page innocarepharma.com/investor/news |
Metrics
| Valuation | |
|---|---|
| Market cap | HK$ 18.6B |
| Market cap (USD) | $ 2.37B |
| P/E | 24.75 |
| PEG | — |
| P/BV | 1.99 |
| P/S | 5.68 |
| P/OCF | 69.56 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | 0.18% |
| Returns | |
|---|---|
| ROE | 8.9% |
| ROI | 8.0% |
| ROIC | 8.0% |
| Profit margin | 27.1% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | Yes |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | 11.6% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 112 |
| Quality score | 29.4% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpAnnouncements and reports published on HKEXnews, newest first, monthly and next-day returns, proxy forms and board-meeting notices included. The link opens the announcement on HKEXnews. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Innocare Pharma Limited
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.









